Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.

Struble, Kimberly

Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. [electronic resource] - Hepatology (Baltimore, Md.) 02 2018 - 482-491 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1527-3350

10.1002/hep.29601 doi


Adult
Aminoisobutyric Acids
Antiviral Agents--administration & dosage
Carbamates--administration & dosage
Cyclopropanes
Drug Therapy, Combination
Genotype
Hepatitis C--classification
Hepatitis C, Chronic--drug therapy
Heterocyclic Compounds, 4 or More Rings--administration & dosage
Humans
Lactams, Macrocyclic
Leucine--analogs & derivatives
Macrocyclic Compounds--administration & dosage
Proline--analogs & derivatives
Quinoxalines
Risk Assessment
Sofosbuvir--administration & dosage
Sulfonamides--administration & dosage
Sustained Virologic Response
United States
United States Food and Drug Administration
Viral Nonstructural Proteins--antagonists & inhibitors